Specifically enrolling patients with disease progression within six months of receiving platinum-based chemotherapy, CheckMate 141 was the first reported, randomized, phase 3 study of a PD-1 inhibitor in HNSCC, and enrolled 361 patients regardless of tumor PD-L1 status. Here, CD274 is linked to head and neck squamous cell carcinoma.